When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EXEL - Calithera's telaglenastat shows positive action in early-stage RCC study; shares up 4%
Exelixis Inc.
Updated data from a Phase 1 clinical trial evaluating Calithera Biosciences' (CALA+4.1%) glutaminase inhibitor telaglenastat, combined with Exelixis' (EXEL-2.8%) Cabometyx (cabozantinib), in previously treated patients with advanced renal cell carcinoma (RCC) showed a positive effect. The results were presented at the ASCO GU Cancers Symposium in San Francisco.
More news on: Calithera Biosciences, Exelixis, Inc., Healthcare stocks news, Stocks on the move,